Form 8-K - Current report:
SEC Accession No. 0001493152-24-041133
Filing Date
2024-10-15
Accepted
2024-10-15 16:22:27
Documents
14
Period of Report
2024-10-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 56823
2 ex10-1.htm EX-10.1 157415
  Complete submission text file 0001493152-24-041133.txt   422088

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ocx-20241011.xsd EX-101.SCH 3012
4 XBRL LABEL FILE ocx-20241011_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE ocx-20241011_pre.xml EX-101.PRE 24164
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3541
Mailing Address 15 CUSHING IRVINE CA 92618
Business Address 15 CUSHING IRVINE CA 92618 949-409-7600
Oncocyte Corp (Filer) CIK: 0001642380 (see all company filings)

EIN.: 271041563 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37648 | Film No.: 241372083
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)